Literature DB >> 24641401

Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients.

Ting Ji1, Zhi-Guo Zheng, Feng-Mei Wang, Li-Jian Xu, Lu-Feng Li, Qi-Hui Cheng, Jiang-Feng Guo, Xian-Feng Ding.   

Abstract

MicroRNAs are a class of small noncoding RNA which play important regulatory roles in a variety of cancers. MiRNA-specific expression profiles have been reported for several pathological conditions. In this study, we combined large scale parallel Solexa sequencing to identify 11 up-regulated miRNAs and 19 down-regulated miRNAs with computational techniques in the sera of ovarian cancer patients while using healthy serum as the control. Among the above, four miRNAs (miR-22, miR-93, miR-106b, miR-451) were validated by quantitative RT-PCR and found to be significantly aberrantly expressed in the serum of ovarian cancer patients (P<0.05). There were no significant differences between samples from cancer stage I/II and III/IV. However, the levels of miR-106b (p=0.003) and miR-451 (p=0.007) were significantly different in those patients under and over 51 yearsof age. MiR-451 and miR-93 were also specific when analyzed with reference to different levels of CA125. This study shows that Solexa sequencing provides a promising method for cancer-related miRNA profiling, and selectively expressed miRNAs could be used as potential serum-based biomarkers for ovarian cancer diagnosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24641401     DOI: 10.7314/apjcp.2014.15.4.1739

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  9 in total

Review 1.  Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.

Authors:  Martina Montagnana; Marco Benati; Elisa Danese
Journal:  Ann Transl Med       Date:  2017-07

2.  Downregulation of miR-22 acts as an unfavorable prognostic biomarker in osteosarcoma.

Authors:  Guangji Wang; Ningjiang Shen; Liang Cheng; Jianping Lin; Kanghua Li
Journal:  Tumour Biol       Date:  2015-05-08

Review 3.  The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.

Authors:  Priya Samuel; David Raul Francisco Carter
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

4.  Identification of miR-93 as a suitable miR for normalizing miRNA in plasma of tuberculosis patients.

Authors:  Simone E Barry; Brian Chan; Magda Ellis; YuRong Yang; Marshall L Plit; Guangyu Guan; Xiaolin Wang; Warwick J Britton; Bernadette M Saunders
Journal:  J Cell Mol Med       Date:  2015-03-08       Impact factor: 5.310

5.  Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients.

Authors:  Xiaodan Meng; Simon A Joosse; Volkmar Müller; Fabian Trillsch; Karin Milde-Langosch; Sven Mahner; Maria Geffken; Klaus Pantel; Heidi Schwarzenbach
Journal:  Br J Cancer       Date:  2015-09-22       Impact factor: 7.640

6.  Extracellular Vesicles from Uterine Aspirates Represent a Promising Source for Screening Markers of Gynecologic Cancers.

Authors:  Gleb O Skryabin; Andrey V Komelkov; Kirill I Zhordania; Dmitry V Bagrov; Svetlana V Vinokurova; Sergey A Galetsky; Nadezhda V Elkina; Darya A Denisova; Adel D Enikeev; Elena M Tchevkina
Journal:  Cells       Date:  2022-03-22       Impact factor: 6.600

Review 7.  New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies.

Authors:  Erika Larrea; Carla Sole; Lorea Manterola; Ibai Goicoechea; María Armesto; María Arestin; María M Caffarel; Angela M Araujo; María Araiz; Marta Fernandez-Mercado; Charles H Lawrie
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

Review 8.  Current clinical application of serum biomarkers to detect ovarian cancer.

Authors:  Marek Nowak; Łukasz Janas; Grzegorz Stachowiak; Tomasz Stetkiewicz; Jacek R Wilczyński
Journal:  Prz Menopauzalny       Date:  2015-11-27

Review 9.  miR-451: A Novel Biomarker and Potential Therapeutic Target for Cancer.

Authors:  Hua Bai; Suhui Wu
Journal:  Onco Targets Ther       Date:  2019-12-16       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.